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Abstract
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is pathologically characterized
by loss of dopaminergic neurons from the substantia nigra, the presence of aggregated α-synuclein (αS) and evidence
of neuroinflammation. Experimental studies have shown that the cerebral injection of recombinant fibrillar αS,
especially in αS transgenic mouse models, can induce the formation and spread of αS inclusion pathology.
However, studies reporting this phenomenon did not consider the presence of lipopolysaccharide (LPS) in the
injected αS, produced in E. coli, as a potential confound. The objectives of this study are to develop a method
to remove the LPS contamination and investigate the differences in pathologies induced by αS containing LPS
or αS highly purified of LPS.
Results and conclusions: We were able to remove >99.5 % of the LPS contamination from the αS preparations
through the addition of a cation exchange step during purification. The αS pathology induced by injection of
fibrils produced from αS containing LPS or purified of LPS, showed a similar distribution pattern; however, there
was less spread into the cortex of the mice injected with αS containing higher levels of LPS. As previously
reported, injection of αS fibrils could induce astrogliosis, and αS inclusions were present within astrocytes in
mice injected with fibrils comprised of αS with or without cation exchange purification. Furthermore, we
identified the presence of αS pathology in ependymal cells in both groups of mice, which suggests the
involvement of a novel mechanism for spread in this model of αS pathology.
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Background
Parkinson’s disease (PD) is characterized by the pro-
found loss of nigral dopaminergic neurons, the presence
of proteinacious inclusions comprised of aggregated α-
synuclein (αS) in some of the remaining neurons, and
neuroinflammation in affected brain regions [1–4]. PD is
related to several other neurodegenerative diseases, in-
cluding dementia with Lewy bodies (DLB), due to the
presence of pathological αS inclusions [5–7]. Studies of
human pathology have supported the notion that αS ag-
gregation may spread along neuroanatomical pathways
associated with disease progression [8, 9].
It is believed that one method involved in the spread
of αS pathology associated with disease progression is
cell-to-cell transmission of aggregated αS seeds followed
by prion-like conformational templating. This notion
has been supported by the presence of αS inclusions
within fetal dopaminergic neuronal transplants in the
brains of PD patients [10–12]. Experimental mouse
studies using recombinant fibrillar αS, produced in bac-
teria, to induce the spread of αS pathology throughout
the neuroaxis of αS transgenic (Tg) and non-Tg mice
have further suggested that αS aggregation may be able
to spread by “prion-like” conformational templating
mechanisms [13–18]. However, most of these studies did
not take into account that the possible presence of bac-
terial endotoxin/lipopolysaccharide (LPS) may confound
some of these results. The importance of this issue is
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underscored by reports that the intracerebral or periph-
eral administration of LPS alone to mice Tg for αS con-
taining the PD-causing A53T mutation (M83 line),
which were used to show cerebral spread of αS inclu-
sion pathology using bacterial recombinant αS aggre-
gates [13, 16], can induce CNS αS inclusion pathology
[19, 20]. LPS is a major component of the E. coli bac-
terial cell wall and is a potent inducer of inflamma-
tion, by activating the toll-like receptor 4 (TLR4) [21,
22], nevertheless, endogenous αS itself can reportedly
trigger an immune response through a similar mech-
anism [23–27].
Activation of the innate neural immune response is a
consistent finding associated with PD and it is believed
to contribute to disease pathogenesis [3, 28, 29], how-
ever it is unknown whether this process is responsible
for the onset of disease, it’s progression and/or if it
exacerbates existing neurodegeneration. Neuroinflam-
mation is evidenced by the presence of astrogliosis, ac-
tivated microglia (the immune cells of the CNS) and
increased levels of proinflammatory cytokines [30–32].
Furthermore, it is believed that a chronic brain inflam-
matory state can be damaging, as factors produced
and released during such a state can cause/add to oxi-
dative stress [32].
In this study we show that αS purified from E. coli
consistently contains LPS that is difficult to com-
pletely remove, likely due the lipid binding and ionic
properties of αS [33]. Nevertheless, performing
stereotaxic brain injections with preformed fibrils
comprised of αS highly purified of LPS compared to
αS with co-purified LPS in αS Tg mice, we demon-
strate similar induction and spread of αS throughout
the neuroaxis. Additionally, we show that the re-
moval of LPS from the injected αS does not affect
the number of GFAP-reactive astrocytes present in
the hippocampus or entorhinal cortex, and αS inclu-
sions are present in astrocytes in both injection
groups. Interestingly, during the course of these
studies, we observed that in this induced model of
αS inclusion pathology there is not only significant
induction of aggregates in neurons and glia, but also
in ependymal cells. This expands the number of cell
types that can contain αS pathology and could have
important implications for the mechanism involved
in the spread of αS inclusion pathology.
Results
Quantification of endotoxin/LPS contamination in
standard αS protein preparations
αS protein was expressed in and purified from E.
coli, which natively contains endotoxins, i.e. LPS.
LPS is an abundant molecule within the membrane
of Gram-negative bacteria, and is a notorious
contaminant of protein purified from E. coli [34, 35].
LPS is a potent activator of the immune response; in-
jection of just 4 ng/kg body weight (approximately
40EU/kg) can cause a dramatic increase in inflamma-
tory markers in humans [36]. The United States
Pharmacopeia (USP) recommends that vaccines/inject-
able medications contain <5EU/kg body weight [37].
It is also well known that it is difficult to completely
remove LPS from bacterial protein preparations due
to its ionic and hydrophobic properties, and the for-
mation of a spectrum of multimeric complexes with
varied size properties [34, 38, 39]. As αS is a lipid
binding protein [33] and it has hydrophobic, nega-
tively charged and positively charged domains (Fig. 1a),
we wanted to assess the extent to which our stand-
ard bacterial protein preparations may be contami-
nated with LPS. We employed the standard LAL in
vitro method and a TLR4 cell responder assay to de-
termine the levels of endotoxin contamination, using
purified endotoxin as our standard (Fig. 1b and c).
We found that our bacterial αS protein preparations
contained varying levels of LPS, as shown for one
preparation in Fig. 1. The TLR4 assay indicates that
there are >50EU/ml in 0.1 μM protein sample (i.e.
>34.6 EU/μg αS protein). Trying different methods,
we found that it was difficult to remove the LPS from
our preparations, but by lowering the pH to 4.2 and
using cation affinity purification with extensive wash-
ing, we were able to remove >99.5 % of the bacterial
endotoxin contamination from our recombinant αS
protein samples, although some residual amounts
(<0.5EU/ml in 1 μM protein sample; <0.035 EU/μg αS
protein) were still detected with the more-sensitive
LAL assay (Fig. 1c). Samples from these same prepa-
rations of recombinant human αS prior to cation ex-
change purification (αS) or after purification (cation
exchanged αS) were fibrillized, sonicated and used for
stereotaxic injection into αS Tg mice. Following sur-
gery, the LAL assay was repeated on the remaining
αS fibrils. We found that although the amount of
endotoxin within the cation exchanged αS fibrils in-
creased (~5EU/ml in 1 μM protein sample; ~0.35EU/
μg αS protein), there was ≥99 % less endotoxin
present in these αS fibrils than in the non-cation ex-
changed αS fibrils.
Effects of endotoxin contamination on the induction and
spread of αS pathology in M83 αS Tg mice
M83 αS Tg mice express human A53T αS driven by
the mouse prion-protein promoter. These mice de-
velop an age-dependent motor phenotype resulting in
paralysis that is associated with the formation of αS
inclusions in the spinal cord, brain stem and midbrain
[40]. These pathological changes can occur between 7
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and 16 months of age in homozygous M83 αS Tg
mice, but later than 22 months of age in hemizygous
mice [40]. Intracerebral injections of preformed αS
amyloid fibrils, generated from recombinant αS pro-
duced in E. coli, have been shown to induce the for-
mation of αS inclusion pathology that spreads from
the site of injection [13, 15, 16]. However, levels of
LPS contamination were not taken into consideration
in these studies, and it was previously reported that
both peripheral or brain injection of LPS can induce
αS inclusion pathology in M83 αS Tg mice [19, 20].
Given that we were able to generate recombinant αS
that is largely devoid of LPS, we tested whether LPS
contamination significantly altered the induction of brain
αS inclusion pathology following intracerebral injection of
preformed amyloid fibrils. Fibrils produced from αS and
cation exchanged αS were stereotaxically injected into the
hippocampus of 2 month old hemizygous M83 αS Tg
mice. Immunohistochemical analysis of the brains and
spinal cords of these mice (Fig. 2a) revealed the presence
of inclusions that were immunoreactive for antibodies to
αS (Syn506), Ser129 phosphorylated αS (pSer129/81A)
and a general inclusion marker (p62) in mice injected with
fibrils produced from αS or cation exchanged αS. Forma-
tion of authentic αS inclusion pathology was also con-
firmed by double-immunofluorescence microscopy with
antibodies to αS (SNL4) and Ser129 phosphorylated αS
(pSer129/81A; Fig. 3). Distribution analysis of the αS
Fig. 1 Assessment of endotoxin/LPS contamination in αS protein preparations. a Schematics showing the charged regions and hydrophobic
regions of αS and LPS. NAC = “non-amyloid-β component of the amyloid plaque” hydrophobic region of αS. (b and c) Average quantification of
endotoxin contaminants in αS protein preparations. Results are also shown for samples that were further purified using High S resin (cation
exchanged). (b) and (c) illustrate contamination in the same sample set, using the Pierce LAL assay and the InvivoGen HEK-Blue-hTLR4 cell culture
system respectively. The hTLR4 assay shows an expanded standard curve. 1 μM αS = 0.0146 mg/ml. White bars represent the endotoxin standard
and black bars represent test samples. Error bars represent the standard error of the mean. AU = absorbance units
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pathology (Fig. 2b) showed a high concentration of inclu-
sions at the site of injection in both sets of mice and quan-
tification of Syn506 staining in this region revealed no
difference between the two groups (Fig. 2c). Pathology
was observed to have spread caudally, to the brainstem
and spinal cord in both groups, with similar frequencies of
inclusions. The only major difference detected between
the distributions of inclusions in the two groups was the
spread of αS pathology into the cortex of the mice. In
mice injected with cation exchanged αS, inclusions ap-
peared with moderate frequency throughout the cortex,
whereas cortical inclusions in the αS injected mice were
rare, and only observed in dorsal regions.
To further assess the involvement of LPS contamin-
ation in driving the formation of αS pathology, we
stereotaxically injected homozygous M83 αS Tg mice
Fig. 2 αS pathology in M83 αS Tg mice following injection of αS or cation exchanged αS fibrils. a Representative immunohistochemical images
of cortical, hippocampal, brainstem, and spinal cord sections of hemizygous M83 αS Tg mice stereotaxically injected in the hippocampus with αS
or LPS purified (cation exchanged) αS. Antibodies to αS (Syn506), to αS phosphorylated at Ser129 (pSer129/81A), and a general inclusion marker
(p62) were used. Scale bar = 50 μm. b Schematic representation of the distribution of αS inclusion pathology in the neuroaxis of hemizygous M83
αS Tg mice injected with αS or cation exchanged αS fibrils. Red dots indicate the sites and amounts of αS pathology. Blue arrows indicate the
site of injection. c Quantification of Syn506 staining in the hippocampus of mice injected with αS or cation exchanged αS fibrils. The p-value was
calculated using a two-tailed t-test. Error bars represent the standard error of the mean
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in the hippocampus with 10 μg of purified LPS, with
an activity of ~0.25 EU/pg (Additional file 1: Figure
S1A). This constitutes greater than 10 million fold
more endotoxin units than were present in the cation
exchanged αS used for injection. We used homozy-
gous mice as they should be more primed for the in-
duction of pathology, but in these studies no αS
inclusion pathology was observed (Fig. 4). Similarly,
injection of PBS into the hippocampus of homozy-
gous M83 αS Tg mice did not induce the formation
of αS inclusion pathology (data not shown) indicating
that it is the injected αS fibrils that are responsible
for the induction of αS inclusions. We confirmed
that the purified LPS was able to induce an inflam-
matory response, by treating primary microglial cul-
tures produced from nTg mice with the same LPS
that was injected. As expected, we observed changes
in morphology of the cells over time; they became
round and swollen with vacuoles evident after 12 h
of treatment with LPS (Additional file 1: Figure S1B).
We also detected a concomitant rise in protein levels of
interleukin-6 (IL-6), a marker of inflammation, within
the media of the LPS treated cells after 6 h of treat-
ment, which increased to 19.6 ng/ml compared to
media from control cells, which remained below the
level of detection (Additional file 1: Figure S1C).
Astrocyte activation and induction of astrocytic αS
inclusion pathology due to hippocampal injection of
recombinant of αS fibrils
We recently reported that the hippocampal injection of
fibrillar αS in M83 αS Tg mice also resulted in the in-
duction of astrogliosis and that a significant proportion
of induced αS inclusion pathology was actually in
glial cells [41]. To assess if the changes in glia were
due to the presence of LPS in the fibrillar αS that
was injected, we assessed the abundance of astroglio-
sis, by staining for GFAP, in the brains of M83 αS Tg
mice that were injected with αS, cation exchanged αS,
LPS or PBS. In this cohort of mice, the density of
Fig. 3 Immunofluorescence analysis of αS pathology in M83 αS Tg mice following injection of αS fibrils. Representative immunofluorescent
images of the cortical, hippocampal, and brainstem regions of hemizygous M83 αS Tg mice injected with αS or cation exchanged αS fibrils,
stained with antibodies to phosphorylated αS (pSer129/81A; red) or αS (SNL4; green) and DAPI (blue). Individual images were overlaid to show
colocalization (Merge). Scale bar = 50 μm
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GFAP-positive astrocytes in the hippocampus and
entorhinal cortex was elevated in αS and LPS injected
mice compared to PBS controls, but did not reach
statistical significance (Fig. 5a). We also assessed
whether there was similar induction of αS inclusion
pathology in glial cells and found that αS inclusions
were present in astrocytes in both αS and cation ex-
changed αS injected mice (Fig. 5b).
Induction of ependymal αS inclusion pathology resulting
from the hippocampal injection of recombinant αS fibrils
Expending the observations of αS inclusion pathology in
glia, we also observed a similar induction of αS inclusions
in ependymal cells of M83 αS Tg mice injected in the
hippocampus with preformed αS fibrils (Fig. 6a and b). In
comparison, αS inclusion pathology within ependymal cells
was not observed in naïve M83 αS Tg mice that become
motor impaired and develop αS inclusions due to aging
(Fig. 6d). To assess if the formation of ependymal αS path-
ology in αS injected M83 αS Tg mice was unique to this
mouse line, we re-examined the pathology in M20 αS Tg
mice that were also challenged with hippocampal injection
of fibrillar αS (Fig. 7a). We found that ependymal αS in-
clusion pathology was also present in these mice, albeit
less abundant than in M83 αS Tg mice. We did not detect
any ependymal cell αS pathology in either mouse line
injected with PBS (Figs. 6c and 7b). Furthermore, injection
of αS fibrils into non-Tg mice did not induce the forma-
tion of αS inclusion pathology within ependymal cells
(Fig. 7c).
Discussion
In this study we showed that recombinant αS prepared
from E. coli can readily contain bacterial endotoxin/
LPS, which most likely occurs due to the complex elec-
trostatic, hydrophobic, and multimeric structure
properties of both αS and LPS [34, 38, 39, 42]. The
identification of LPS contamination in these protein
preparations is an important finding since recombinant
αS has been injected into αS Tg mice, in the form of fi-
brillar seeds, in order to induce pathology [13, 15–18].
Since LPS is a potent inflammagen, and chronic neuro-
inflammation is believed to play a substantial role in
the development and/or progression of a number of
neurodegenerative diseases, including PD [6, 28, 29,
43, 44], it stands to reason that its presence would be a
significant confound. Indeed it has been published that
a single injection of LPS in the brain or peripherally is
sufficient, in M83 αS Tg mice, to induce αS inclusion
pathology [19, 20]. To assess for the involvement of
the contaminating LPS in the induction of αS path-
ology in these mice, we developed a purification proto-
col that eliminates almost all of the LPS contaminants
(>99.5 %), by exploiting the presence of a region of
positive charge that is present in αS, but not in LPS.
Stereotaxic hippocampal injections in M83 αS Tg mice,
using fibrils prepared from αS with or without the add-
itional purification (cation exchanged αS and αS, re-
spectively), induced similar amounts and distributions
of αS inclusion pathology except in the cortex, where
we observed fewer αS inclusions in the αS injected
mice. Moreover, we were unable to reproduce the re-
sults published by Gao and colleagues [19, 20]; we ob-
served no αS inclusion pathology in homozygous M83
αS Tg mice injected with purified LPS. However, there
were major differences between these studies. First, we
injected into the hippocampus whereas Gao et al. injected
LPS into the substantia nigra. The dopaminergic cells of
the substantia nigra are particularly vulnerable to inflam-
matory/oxidative stress that can be induced by treatment
with LPS, and so the overexpressed αS may be induced to
aggregate due to additional adverse cellular mechanisms.
Fig. 4 Immunohistochemical analysis showing the paucity of αS pathology in M83 αS Tg mice injected with LPS. Representative
immunohistochemical images from the cortex, hippocampus, brainstem, and spinal cord of homozygous M83 αS Tg mice injected with LPS,
using antibodies to αS (Syn506), to αS phosphorylated at Ser129 (pSer129/81A), and a general inclusion marker (p62). No immunoreactive
inclusions were identified in these mice. Scale bar = 50 μm
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Second, the age at which the injections were carried out
was different between the two studies. Our mice were
injected at 2 months of age, an age which is much earlier
than when naïve mice develop pathology or motor symp-
toms. Gao et al. injected their mice at 7 or 12 months of
age, for intraperitoneal and brain injection respectively,
which is around the age at which these mice typically de-
velop pathology. They reported that the mice did not
present with an overt neurological phenotype at the time
of injection however, the mice could already have αS path-
ology within their brains or at least would be more prone
to developing αS pathology due to a neurological insult.
These factors could provide a possible explanation for the
differences in results observed in the two studies. The LPS
used was derived from the same strain of E. coli (E. coli
0111:B4), and we injected twice the amount that Gao et al.
injected (10ug versus 5ug), so the amount and type of LPS
is most likely not responsible for the differences seen.
As LPS is known to invoke an inflammatory response,
we looked for evidence of neuroinflammation in the
mice. We saw the greatest number of astrocytes within
the hippocampus and entorhinal cortex of αS injected
mice, with cation exchanged αS and LPS injected mice
also having elevated numbers of astrocytes compared to
Fig. 5 Astrogliosis and αS inclusions within astrocytes, in M83 αS Tg mice injected with αS fibrils. a Percentage of GFAP-positive astrocytes per
field area in the hippocampus (left) and entorhinal cortex (right) of M83 αS Tg mice stereotaxically injected with αS or cation exchanged αS fibrils
or LPS in the hippocampus, versus PBS injected mice. P-values were determined by one-way ANOVA analyses. b Representative images of the
hippocampus, showing double immunofluorescent staining with pSer129/81A (αS phosphorylated at Ser129) and GFAP. Individual images were
overlaid (Merge) to show colocalization. Scale bar = 50 μm
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PBS injected mice. However, none of these reached stat-
istical significance. This slight increase in astrogliosis
provides a potential explanation to the reduced spread
of αS pathology into the cortex of αS injected mice. The
presence of LPS within the injected sample may be indu-
cing an acute inflammatory response which could result in
the removal of some of the αS seeds. This would lead to
the reduction of spread of pathology, with the number of
astrocytes returning to near-normal within the 3 months
before the mice were sacrificed. Nevertheless, αS inclusions
were present within astrocytes in both αS and cation ex-
changed αS fibril injected mice.
Serendipitously, we observed the presence of αS inclu-
sions within ependymal cells in the αS (both αS and
Fig. 6 Immunohistochemical analysis showing ependymal cell αS pathology in M83 αS Tg mice injected with αS fibrils. Representative
immunohistochemical images of hemizygous M83 αS Tg mice injected with αS fibrils (a) or cation exchanged αS fibrils (b), and homozygous M83
αS Tg mice injected with PBS (c), or aged until motor impairments were observed (d). Images showing midline (left; below showing higher
magnification) and lateral ventricle (right) stained with antibodies to αS phosphorylated at Ser129 (pSer129/81A), αS (Syn506) and a general
inclusion marker (p62). Scale bars = 100 μm
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cation exchanged αS), but not in LPS or PBS injected
M83 αS Tg mice. Furthermore, this ependymal αS inclu-
sion pathology was not present in aged, motor impaired
M83 αS Tg mice. Subsequent examination of M20 αS Tg
mice injected with αS fibrils revealed a similar but re-
duced amount of αS pathology within the ependymal
cells, and non-Tg mice injected with αS fibrils did not
develop ependymal cell αS pathology. This suggests that
ependymal αS inclusion pathology is specific to αS fibril
injected αS Tg mice. Pathological studies of human α-
synucleinopathies have described αS inclusions within
astrocytes, oligodendrocytes, in the sub-ependymal area
and between ependymal cells [45, 46].
The presence of αS inclusion pathology in ependymal
cells provides a new level of complexity in interpreting
the mechanism(s) involved in the spread of αS path-
ology, as it might provide additional explanations for the
potent progression of this phenomenon in these mouse
models. As ependymal cells line the ventricular system
of the central nervous system, the uptake and release of
αS aggregates from these cells into the cerebrospinal
fluid would provide more widespread access to the brain
and spinal cord, which could explain the efficient spread
of αS inclusion pathology throughout the neuroaxis of
these mice. Although some cell culture studies have pro-
vided decent evidence that αS conformational templat-
ing can occur under certain cellular conditions [47–49],
the mechanisms involved in whole animal studies are
more challenging to delineate due to the complex inter-
actions of the biological mechanisms that can be
Fig. 7 Immunohistochemical analysis showing ependymal cell αS pathology in M20 αS Tg mice injected with αS fibrils. Representative
immunohistochemical images of hemizygous M20 αS Tg mice injected with αS fibrils (a) or PBS (b) and nTg mice injected with αS fibrils (c).
Images showing midline (left; below is a higher magnification) and lateral ventricle (right) stained with antibodies to αS phosphorylated at Ser129
(pSer129/81A), αS (Syn506) and a general inclusion marker (p62). Scale bars = 100 μm
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involved [50, 51]. Given our new findings, additional
studies are required to determine the relative contribu-
tions of various physiological and cellular mechanisms
to the induction and spread of αS inclusion pathology in
the αS fibril injected αS Tg mouse models.
Conclusions
We have shown here that the presence of LPS in bac-
terially produced αS is not a major factor involved in
the induction of αS inclusion pathology resulting from
the cerebral injection of preformed recombinant αS
amyloid seeds in M83 αS Tg mice. However, the pres-
ence of LPS levels should be considered when using
bacterially expressed αS in biological studies. Further-
more we demonstrated the presence of αS inclusions
within ependymal cells of αS Tg mice injected in the
cerebrum with αS fibrils to induce the spread of αS in-
clusion pathology, which puts forth a novel mechan-




pSer129, also known as clone 81A, is a mouse monoclonal
antibody that reacts with αS phosphorylated at Ser129
[52]. Syn506 is a conformational anti-αS mouse monoclo-
nal antibody that preferentially detects αS in pathological
inclusions [53, 54]. SNL4 is a rabbit polyclonal antibody
that recognizes N-terminal residues 2–12 in αS [55]. Anti-
p62 is a rabbit polyclonal antibody that is a general protein
inclusion marker (SQSTM1; ProteinTech). Rabbit poly-
clonal anti-GFAP detects glial fibrillary acidic protein, and
is a marker of astrocytes (Dako).
Recombinant αS expression and purification
The bacterial expression plasmid; pRK172, encoding full
length human αS was previously described [56]. Recom-
binant αS was expressed in BL21(DE3)/RIL E. coli (Agilent
Technologies) and purified by size exclusion chromatog-
raphy and subsequent Mono-Q ion exchange chromatog-
raphy as previously described [56, 57]. To further purify
αS and remove LPS contamination, we tested a number of
different absorption resins including hydroxyapatite (Bio-
Rad), hydrophobic resins, lipid removing agent (LRA;
Sigma) and Mono-S ion exchange (Bio-Rad), using buffers
with a range of pH values. In the most successful ap-
proach, samples were purified by High S Support cation
exchange chromatography (Bio-Rad). The protein was ex-
changed with 20 mM PIPES, pH4.2, bound to the High S
resin, extensively washed with 20 mM PIPES, pH4.2
and eluted with 20 mM PIPES, pH4.2, 1 M NaCl. The
purified protein was then exchanged with PBS. Protein
concentrations were quantified using the bicinchoninic
acid (BCA) assay (Thermo Scientific), using bovine serum
albumin as a standard (Pierce Biotechnology).
Detection and quantification of endotoxin contamination
To assay for the presence of lipopolysaccharide (LPS) in
the αS protein preparations, two methods were employed:
1) the HEK-Blue-hTLR4 cell culture system and QUANTI-
Blue media (InvivoGen) according to the manufacturer’s
protocol, and 2) the Pierce LAL Chromogenic Endotoxin
Quantitation Kit (Thermo Scientific) according to the
manufacturer’s protocol, using the included endotoxin
standard for both assays. Standards and protein samples
were prepared by dilution in endotoxin free water. Absorb-
ance values were determined by plate reader, and for some
samples were above the range of detection.
Fibril formation of recombinant αS proteins
Fibrils were formed by incubating the αS proteins at
5 mg/ml in sterile PBS at 37 °C with constant shaking at
1050 rpm (Thermomixer R, Eppendorf) for 48 h. Fibril
formation was monitored by (trans,trans)-1-bromo-2,5-
bis-(4-hydroxy)styrylbenzene (K114) fluorometry as pre-
viously described [58]. Fibrils were prepared for injection
by diluting the samples in sterile PBS followed by mild
sonication in a water bath for 2 h.
Mouse husbandry and stereotaxic brain injections
All procedures were performed according to the NIH
Guide for the Care and Use of Experimental Animals
and were approved by the University of Florida Institu-
tional Animal Care and Use Committee. Tg mice ex-
pressing wild-type human αS (M20 line) or human αS
containing the A53T mutation (M83 line), were previ-
ously described [40]. Two month old M83 αS Tg mice
were bilaterally stereotaxically injected in the hippo-
campus (coordinates from Bregma: A/P −1.7, L ±1.6,
D/V −2.0) with 2.5 μl αS fibrils (1.6 mg/mL) or αS fi-
brils purified of LPS (1.6 mg/ml), or 2.0 μl LPS (5 mg/
ml; E. coli 0111:B4; Sigma) or sterile PBS (summarized
in Table 1), at a rate of 0.2 μl/minute. A cohort of two
month old M20 Tg mice and non-Tg mice was also
stereotaxically injected in the hippocampus with 2.0 μl
αS fibrils (2.0 mg/mL) or sterile PBS (M20 αS Tg mice
only). Mice were sacrificed by CO2 euthanization
followed by cardiac perfusion with PBS/heparin. The
brain and spinal cord were harvested and fixed in 70 %
ethanol/150 mM NaCl. The tissue was then dehydrated,
paraffinized as previously described [59] and cut into
7 μm sections.
Immunohistochemistry
Tissue sections were deparaffinized in xylene and rehy-
drated in a descending ethanol series (100 %, 90 %, 70 %).
Antigen retrieval was performed by incubation in a
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steam bath for 30 min. Endogenous peroxidase activity
was quenched, and samples were blocked with 2 % fetal
bovine serum (FBS)/0.1 M Tris pH7.6. Primary anti-
bodies were diluted in blocking solution and applied to
samples for overnight incubation at 4 °C. Anti-rabbit
or anti-mouse biotinylated antibodies were diluted in
blocking solution and applied to sections for an hour
at room temperature. Next, the avidin-biotin complex
(ABC) Vectastain system (Vector Laboratories) was
employed and immunocomplexes were visualized with
the chromogen 3,3’-diaminobenzidine (DAB). Sections
were counterstained with hematoxylin followed by dehy-
dration in an ascending series of ethanols (70 %, 90 %,
100 %) and xylene. Sections were coverslipped using cyto-
seal and dried before scanning using an Aperio ScanScope
CS (40x magnification; Aperio Technologies Inc.). Repre-
sentative images (for figures) and images showing the
hippocampus or the entorhinal cortex (for astrocyte count-
ing) were taken using the ImageScope TM software (Aperio
Technologies Inc.).
Double immunofluorescence
Tissue sections were deparaffinized and rehydrated, and
antigen retrieval was performed as described in the im-
munohistochemistry methods. Sections were blocked
with 5 % dry milk/0.1 M Tris pH7.6. Primary antibodies
were diluted in blocking solution and applied to sections
for overnight incubation at 4 °C. Sections were washed
with 0.1 M Tris pH7.6 and secondary antibodies conju-
gated to Alexa Fluor 488 or 594 fluorophores (Life Tech-
nologies) were diluted in blocking solution and applied to
sections for 2 h at room temperature in the dark. Sections
were then treated with sudan black to block lipofuscin au-
tofluorescence. Nuclei were stained with 4’,6-diamidino-2-
phenylindole (DAPI; Pierce) and sections were mounted
using Fluoromount-G (SouthernBiotech). Pictures were
obtained using an Olympus BX51 fluorescent microscope
and images were overlaid using Photoshop CS6 software.
Quantification of staining, cell counts and statistical
analyses
Scanned images of Syn506 stained sections were loaded
into ImageScope TM software. The hippocampal areas
were outlined and analyzed for the abundance of DAB
positive pixels. The burden was calculated by dividing
the number of positive pixels by the area. Images ob-
tained from the CA2/3 of the hippocampus and entorhi-
nal cortex of GFAP-DAB stained sections were taken at
10x using ImageScope TM software. The images were
randomized and coded, and the numbers of GFAP posi-
tive cells were counted by a single user, blinded to the
experimental conditions. Two-tailed t-tests and one-way
analysis of variance (ANOVA) with post-hoc Dunnett’s
multiple comparison tests were performed in GraphPad
Prism v5.03 software.
Activation of an inflammatory response in primary
microglia by purified LPS
The cortices from B6/C3H P0-P2 mice were isolated as
previously described [60]. The mixed glial cultures were
maintained in DMEM/10 % FBS with 100 units/ml
penicillin and 100 μg/ml streptomycin. After 10–14
days of incubation, flasks were shaken at 150 rpm for
30 min at 37 °C to dislodge microglia from the astro-
cyte layer. The microglial cells were then re-plated into
6 well culture dishes in DMEM/10 % FBS with 100
units/ml penicillin and 100 μg/ml streptomycin. All
cells were maintained at 37 °C in a humidified incubator
with 5 % CO2. When the primary microglial cultures
reached ~60 % confluency, the media was removed from
the wells and was replaced with 2 ml of media containing
50 ng/ml LPS. Control wells received the same treat-
ment, without the addition of LPS (n = 3/group). The
cultures were returned to the incubator for 1, 6 or 12 h.
Following incubation, images of the cultures were ob-
tained using an EVOS FL cell imaging system (AMG).
Then, the media was removed, mixed with protease in-
hibitors and aliquoted. The amount of IL-6 within the
Table 1 Summary of αS Tg mice stereotaxically injected in the hippocampus
Mouse line Number of mice Months post-injection at death Inoculate Volume (μl)
M83+/− 4 3 αS (1.6 mg/ml) 2.5
M83+/− 4 3 Cation-exchanged αS (1.6 mg/ml) 2.5
M83+/+ 4 2 LPS (5 mg/ml) 2
M83+/+ 4 2 PBS 2
M20+/- 4 4 αS (2 mg/ml) 2
M20+/- 2 2 PBS 2
M20+/- 5 4 PBS 2
M20+/- 4 7 PBS 2
nTg 4 4 αS (2 mg/ml) 2
+/− = hemizygous, +/+ = homozygous
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media (diluted 1:50) was determined using a BD OptEIA
mouse IL-6 ELISA kit according to the manufacturer’s
protocol (BD biosciences).
Additional file
Additional file 1: Figure S1. Assessment of endotoxin activity within
purified LPS. (A) Comparison of the activity of purified LPS (E. coli
0111:B4), that was used for cerebral injection, to standard endotoxin
using the Pierce LAL assay. White bars represent the endotoxin standard
and black bars represent test samples. (B) Images showing the morphology
of primary microglia in culture following 6 and 12 h of treatment with 50 ng/
ml purified LPS or nothing (control). Scale bar = 200 μm. (C) Detection of IL-6
within the media (diluted 1:50, 100 μl) taken from primary microglia cultures
after 1 or 6 h of treatment with 50 ng/ml purified LPS or nothing (control).
White bars represent IL-6 standard. Black bars represent test samples.
Error bars represent the standard error of the mean. AU = absorbance
units. (TIFF 4630 kb)
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